JP2018513155A5 - - Google Patents

Info

Publication number

JP2018513155A5

JP2018513155A5 JP2017553926A JP2017553926A JP2018513155A5 JP 2018513155 A5 JP2018513155 A5 JP 2018513155A5 JP 2017553926 A JP2017553926 A JP 2017553926A JP 2017553926 A JP2017553926 A JP 2017553926A JP 2018513155 A5 JP2018513155 A5 JP 2018513155A5

Authority

JP

Japan

Prior art keywords

combination

composition

patient

administered

hrg

Prior art date

2016-04-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 102000048238 Neuregulin-1 Human genes 0.000 claims description 32
• 108090000556 Neuregulin-1 Proteins 0.000 claims description 32
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 32
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 32
• 238000000034 method Methods 0.000 claims description 23
• 239000000203 mixture Substances 0.000 claims description 21
• 206010028980 Neoplasm Diseases 0.000 claims description 18
• 238000009121 systemic therapy Methods 0.000 claims description 13
• 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
• 201000011510 cancer Diseases 0.000 claims description 9
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
• 229960003668 docetaxel Drugs 0.000 claims description 6
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 6
• 229960005079 pemetrexed Drugs 0.000 claims description 6
• 230000001394 metastastic effect Effects 0.000 claims description 5
• 229910052697 platinum Inorganic materials 0.000 claims description 5
• 238000003757 reverse transcription PCR Methods 0.000 claims description 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
• 206010027476 Metastases Diseases 0.000 claims description 4
• 201000010099 disease Diseases 0.000 claims description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
• 238000007901 in situ hybridization Methods 0.000 claims description 4
• 108020004999 messenger RNA Proteins 0.000 claims description 4
• 230000009401 metastasis Effects 0.000 claims description 4
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
• 230000001575 pathological effect Effects 0.000 claims description 4
• 238000005549 size reduction Methods 0.000 claims description 4
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
• 230000001225 therapeutic effect Effects 0.000 claims description 4
• 230000002250 progressing effect Effects 0.000 claims 2
• 238000003556 assay Methods 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 230000000118 anti-neoplastic effect Effects 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 1